Trevi Therapeutics Executive Team to Attend Key Conferences This September
Trevi Therapeutics to Showcase Innovations at September Conferences
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a pioneering clinical-stage biopharmaceutical firm, is poised to make a notable presence in the medical community this September. The company is set to participate in several prestigious conferences, showcasing its investigational therapy Haduvio™ (oral nalbuphine ER) aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and other chronic cough conditions.
Upcoming Conferences
2025 Wells Fargo Healthcare Conference
Date: September 3-5, 2025
Location: Everett, Massachusetts
Trevi's President and CEO, Jennifer Good, along with Chief Commercial Officer Farrell Simon will be in attendance to discuss the potential of Haduvio in managing chronic cough associated with IPF.
Cantor Global Healthcare Conference 2025
Date: September 3-5, 2025
Location: New York, New York
Again, CEO Jennifer Good will present alongside Chief Development Officer James Cassella, as they delve into the development updates of Haduvio and address investor inquiries.
Morgan Stanley 23rd Annual Global Healthcare Conference
Date: September 8-10, 2025
Live Fireside Chat: September 9, 4:05 PM ET
Hosted in New York, this platform will further spotlight Haduvio's clinical potential as Trevi representatives engage with healthcare stakeholders and investors.
H.C. Wainwright Co. 27th Annual Global Investment Conference
Date: September 8-10, 2025
Location: New York, New York
The same leadership team will again engage attendees to accentuate the urgency and importance of addressing chronic cough—and how Trevi’s investigational therapy stands at the forefront of this challenge.
2025 Leerink Partners Biopharma Summit
Date: September 17-19, 2025
Location: Healdsburg, California
Jennifer Good will present at this summit, providing insights into the strategic direction of Trevi Therapeutics and the vital role of Haduvio.
European Respiratory Society (ERS) Congress
Date: September 27 - October 1, 2025
Location: Amsterdam, Netherlands
A broader audience will hear from Trevi’s team, including Good, Cassella, and other experts, emphasizing the groundbreaking research surrounding Haduvio in the global context of respiratory health.
What is Haduvio?
Haduvio represents the first investigational therapy to demonstrate a significant reduction in cough frequency during clinical trials. This therapy is critically needed as chronic cough impacts a significant percentage of IPF patients—up to 85% exhibit this debilitating symptom, with roughly 150,000 individuals diagnosed with IPF in the U.S. alone.
Chronic cough can lead to severe social and mental health implications for affected patients, highlighting the urgent need for effective treatment solutions. With Haduvio, Trevi Therapeutics aims to provide relief by targeting both central and peripheral aspects of the cough reflex arc and approaching the condition from a dual-action perspective as a kappa agonist and mu antagonist.
Despite no currently approved therapies for chronic cough related to IPF in the U.S., Trevi's ongoing clinical trials indicate promise that could lead to a breakthrough in treatment options.
Conclusion
As Trevi Therapeutics gears up for these influential conferences, the company is not only seeking to garner attention for Haduvio but also to advocate for the countless patients affected by chronic cough related to lung diseases. With leadership poised to engage directly with investors and healthcare professionals, Trevi stands poised for significant advancements in how chronic cough is managed in various healthcare settings.
For additional details on Trevi Therapeutics and updates on Haduvio, visit www.TreviTherapeutics.com or follow the company on X (formerly Twitter) and LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.